title: Development of a centrifugal pump with improved antithrombogenicity and hemolytic property for chronic circulatory support.
abstract: A centrifugal pump with a unique structure has been developed for chronic support. The pump is driven by a magnetic coupling and has no rotating shaft, no seal around the rotating part, and a balancing hole at the center of the impeller and the thrust bearing. The pump was improved in stepwise fashion to realize good antithrombogenicity and low hemolysis. The first pump, the National Cardiovascular Center (NCVC)-0, had an impeller with 4 rectangular and curved vanes; 6 triangularly shaped curved vanes were employed in the second model, the NCVC-1, to reduce trauma to the blood. In the third design, the NCVC-2, the central hole was enlarged, and the thrust bearing shoulder was rounded so that blood washing was enhanced around the impeller; stream lines also were smoothed for improved antithrombogenicity. The hemolytic property of the device was evaluated in vitro with heparinized fresh goat blood; hemolysis indexes of the NCVC-0, -1, and -2 were 0.05, 0.01, and 0.006 g per 100 L, respectively. Antithrombogenicity of the pumps was examined in animal experiments as a left heart bypass device in goals weighing 52-75 kg. Six NCVC-0 pumps were driven for 14 to 33 (22.0 +/- 7.6) days in goats receiving the antiplatelet drug cilostazol orally. Four NCVC-1 pumps ran for 1 to 80 (28.5 +/- 30.6) days with the same drug regimen in 2 cases and with no anticoagulation therapy in 2 cases. After 3 preliminary 1-week tests of NCVC-2 pumps in animals, the pump was installed in 3 goats; 2 pumps were still running on the 182nd and 58th pumping day. Intracorporeal implantation also was attempted successfully. The results indicate that this pump has promising features for chronic support although longer term and additional evaluations are necessary.
authors.affiliation: Department of Artificial Organs, National Cardiovascular Center, Osaka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Taenaka
authors.forename: Y
authors.initials: Y
authors.lastname: Wakisaka
authors.forename: T
authors.initials: T
authors.lastname: Masuzawa
authors.forename: E
authors.initials: E
authors.lastname: Tatsumi
authors.forename: K
authors.initials: K
authors.lastname: Toda
authors.forename: K
authors.initials: K
authors.lastname: Miyazaki
authors.forename: K
authors.initials: K
authors.lastname: Eya
authors.forename: Y
authors.initials: Y
authors.lastname: Baba
authors.forename: T
authors.initials: T
authors.lastname: Nakatani
authors.forename: T
authors.initials: T
authors.lastname: Ohno
authors.forename: T
authors.initials: T
authors.lastname: Nishimura
authors.forename: H
authors.initials: H
authors.lastname: Takano
mesh_terms: D000818:Animals; D002498:Centrifugation; D004389:Durable Medical Equipment / Q000592:standards; D006041:Goats; D018611:Heart Bypass, Left; D006353:Heart-Assist Devices / Q000009:adverse effects / Q000592:standards / Q000639:trends*; D006461:Hemolysis; D006801:Humans; D066298:In Vitro Techniques; D007564:Japan; D011183:Postoperative Complications; D013927:Thrombosis / Q000517:prevention & control*